Page 21234..1020..»

Category Archives: Global News Feed

Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

Posted: January 2, 2025 at 2:44 am

Wuxi, China, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (Nasdaq: PHH) (the “Company”), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the closing of its initial public offering (the “Offering”) of 1,200,000 ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per ordinary share. The Ordinary Shares began trading on the Nasdaq Capital Market on December 27, 2024 under the ticker symbol “PHH.”

Visit link:
Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

Posted in Global News Feed | Comments Off on Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted: January 2, 2025 at 2:44 am

CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more from the original source:
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted in Global News Feed | Comments Off on Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Posted: January 2, 2025 at 2:44 am

BOTHELL, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain. This randomized, double-blind, placebo-controlled Phase 2a study is evaluating the safety, tolerability, pharmacokinetics (PK), antiviral activity and clinical measurements of CC-42344 at a single site in the United Kingdom.

See the original post:
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Posted in Global News Feed | Comments Off on Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants

Posted: January 2, 2025 at 2:44 am

DALLAS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced instructions for retail investors on how to exercise any publicly-traded warrants (NASDAQ: MDAIW). The warrant exercise process includes the following steps:

Read the original here:
Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants

Posted in Global News Feed | Comments Off on Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Posted: January 2, 2025 at 2:44 am

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —

The rest is here:
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Posted in Global News Feed | Comments Off on HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Posted: January 2, 2025 at 2:44 am

Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its nanoparticle-based delivery platform was successfully tested also for circular mRNA. In vitro experiments demonstrated successful transfection of cells and significantly higher protein expression than with linear mRNA, based on which the Company has filed a provisional patent application with the United States Patent Office (USPTO). Altamira will start offering its platform to biotech and pharma companies for use with circular RNA under the CycloPhore™ label, complementing its offerings for siRNA (OligoPhore™) and mRNA (SemaPhore™).

Read more here:
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Posted in Global News Feed | Comments Off on Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Firefly Neuroscience Closes on Financing of up to $12.4 Million

Posted: January 2, 2025 at 2:44 am

TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the closing of up to $12.4 million consisting of $2.4 million up front in the form of senior secured convertible notes at $3.00 per share, subject to adjustment, and an equity line of credit (the “ELOC”) for up to $10 million. The proceeds from these financings will be used for growth, commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology, and general working capital purposes.

Read the original:
Firefly Neuroscience Closes on Financing of up to $12.4 Million

Posted in Global News Feed | Comments Off on Firefly Neuroscience Closes on Financing of up to $12.4 Million

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Posted: January 2, 2025 at 2:44 am

TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the renewal of its approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children with autism spectrum disorder ("ASD"). SCI-210 is a proprietary combination of cannabidiol (“CBD”) and CannAmide™.

Read more here:
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Posted in Global News Feed | Comments Off on SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET…

Posted: January 2, 2025 at 2:44 am

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca.

See the article here:
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET...

Posted in Global News Feed | Comments Off on HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET…

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Posted: January 2, 2025 at 2:44 am

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

Go here to see the original:
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Posted in Global News Feed | Comments Off on Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Page 21234..1020..»